TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01842542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroStar Transcranial Magnetic Stimulation (TMS)
Description: Acute phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, five times weekly for up to 8 weeks.~3 week taper phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, 3 times during the first week, 2 times during the second week and one time during the third week. In addition to treatments, patients may receive treatment as usual at the direction of their treating physician.
Study: NCT04796389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Preferred music of the participant administered using headphones.
Study: NCT01898442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 180mg
Description: Rndomization to standard or high ticagrelor loading dose regimens

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 270mg
Description: Randomization to standard or high loading dose regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 360mg
Description: Randomization to standrad or high loading dose regimen
Study: NCT02650934

Intervention type: PROCEDURE
Intervention: Percutanous coronary intervention

Intervention type: PROCEDURE
Intervention: Percutanous coronary intervention
Study: NCT00043407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG 7909
Description: In the phase I portion of the protocol, patients will be included in escalating dose groups: 0.08, 0.12, 0.16, 0.36, 0.54 or 0.81 mg/kg of CPG 7909 Injection. Patients will be treated once weekly subcutaneously for 24 weeks. In the Phase II portion of the trial patients will be treated at the MTD or the highest dose of 0.81 mg/kg identified in the Phase I dose escalation portion of the trial. All patients in Phase I and Phase II will be treated until disease progression or a maximum of 24 weeks.
Study: NCT03284593

Intervention type: DRUG
Intervention: intensive chemotherapy

Intervention type: DRUG
Intervention: Azacitidine
Study: NCT04091464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Backward Walking Training
Description: Training will consist of BW training on both a treadmill and overground. All participants will receive 1x/week training with a trained member of the research team, who will progress the participant week-to-week and ensure safety. Treadmill speed will be determined by baseline BW walking speed and incrementally increased with each training week to subject tolerance. Participants will follow a home exercise program for the remainder of the week that includes BW, backward stepping, and functional exercises that incorporate BW movements.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Forward Walking Training
Description: Training will consist of FW training on both treadmill and overground. All participants will receive 1x/week training with a trained member of the research team, who will progress the participant week-to-week and ensure safety. Treadmill speed will be determined by baseline FW walking speed and incrementally increased with each training week to subject tolerance. Participants will follow a home exercise program for the remainder of the week that includes FW, forward stepping, and functional exercises that incorporate FW movements.
Study: NCT04171921

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic ventral hernia repair
Description: Laparoscopic robotically assisted trans-abdominal pre-peritoneal epigastric or umbilical hernia repair with closure of fascial defect and non-adsorbable mesh reinforcement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open ventral hernia repair
Description: Standard open pre-peritoneal epigastric or umbilical hernia repair with closure of fascial defect and non-adsorbable mesh reinforcement
Study: NCT04499014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: 5 days a week, a total of 10 sessions

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ultrasound
Description: 5 days a week, a total of 10 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: 5 days a week, a total of 10 sessions
Study: NCT02314169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study: NCT00460707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casopitant 150 mg
Description: Casopitant 150 mg will be available as white, film-coated tablets. Casopitant tablets will be taken with 240 milliliters (mL) of water at room temperature on an empty stomach.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casopitant 150 mg
Description: Casopitant 150 mg will be available as white, film-coated tablets. Casopitant tablets will be taken with 240 milliliters (mL) of water at room temperature on an empty stomach.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Ketoconazole will be available as 200 mg tablets which will be taken with 240 mL of water on an empty stomach (after a 2 hour fast on Day 4 of Treatment Period 2 and after a 1 hour fast on all other dosing days).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketoconazole
Description: Ketoconazole will be available as 200 mg tablets which will be taken with 240 mL of water on an empty stomach (after a 2 hour fast on Day 4 of Treatment Period 2 and after a 1 hour fast on all other dosing days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Ketoconazole will be available as 200 mg tablets which will be taken with 240 mL of water on an empty stomach (after a 2 hour fast on Day 4 of Treatment Period 2 and after a 1 hour fast on all other dosing days).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Casopitant 150 mg matching placebo
Description: Casopitant 150 mg matching placebo will be available as white, film-coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casopitant 50 mg
Description: Casopitant 50 mg will be available as pale orange, film-coated tablets. Casopitant tablets will be taken with 240 mL of water at room temperature on an empty stomach.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casopitant 50 mg
Description: Casopitant 50 mg will be available as pale orange, film-coated tablets. Casopitant tablets will be taken with 240 mL of water at room temperature on an empty stomach.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Casopitant 50 mg matching placebo
Description: Casopitant 50 mg matching placebo will be available as pale orange, film-coated tablets.
Study: NCT00335959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 850 mg/m2/dose PO q 12 hours Days 1-14 and 22-35. 650 mg/m2/dose PO q 12 hours Days 43-77.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 130 mg/m2 by 2-hour infusion Days 1 and 22

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Distal subtotal gastrectomy, total gastrectomy, or proximal gastrectomy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Beginning Day 43, patients will be treated 5 days/week at 180 cGy/day times 25 fractions to a total dose of 4,500 cGy.
Study: NCT02314169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT03994614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEAS
Description: Patients in the experimental group will be given TEAS treatment for 12 weeks prior to COS. The patients will be given three times acupuncture every week except menstruation. The acupuncture acupoint locations are as follows: head acupoint Baihui(DU20), abdominal acupoint Zhongji (RN3), Guanyuan (RN4), Zigong(EX-CA1), leg acupoint Sanyinjiao(SP6), waist acupoint Shenyu (BL23) and Guanyuanyu(BL26).
Study: NCT03145662

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high pressure balloon
Description: high pressure balloon will be used to treat stenosis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cutting balloon
Description: cutting balloon will be used to treat stenosis
Study: NCT01696149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical nerve stimulation
Description: All subjects participated, randomly, in a 4 Hz TENS session, a 110 Hz TENS session, and a control (off-TENS) session. Each session consisted of a 20- minute stimulation period and a 10-minute follow up period.
Study: NCT00732680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: 10 Units of Botulinum Toxin Type A injected into the dilator nasalis muscle on each side of the nose.
Study: NCT03532815

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Modification
Study: NCT02432391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GEM
Description: GEM is an integrated lifestyle modification program that focuses on reducing postprandial blood glucose through replacing high with low glycemic load foods and increasing routine physical activity guided by systematic blood glucose monitoring.
Study: NCT01472965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethanol
Description: 70% ethanol catheter lock therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: heparin-saline placebo
Description: heparin-saline placebo catheter lock therapy
Study: NCT01022775

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic humeral centering
Description: Dynamic humeral centering performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nonspecific mobilisation
Description: Nonspecific mobilisation performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
Study: NCT01028248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab (Lucentis)
Description: 0.5mg and 2.0mg dose of Ranibizumab 0.05ml administered intravitreally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab (Lucentis)
Description: 0.5mg and 2.0mg dose of Ranibizumab 0.05ml administered intravitreally
Study: NCT04441476

Intervention type: OTHER
Intervention: Questionnaires
Description: An online questionnaire (Limesurvey platform) will be made available at 4 different times (M0, M1, M2 and M6).~* The first questionnaires (M0 and M1) will include a component for professional characterization. Generic and specific stress factors related to ICU and the current pandemic and collective and individual defensive strategies will also be collected in M0 and M1.~* At M2 and M6, the traumatic impact of the crisis, burnout, signs of depression and recourse to internal or external support in the department (occupational medicine, support unit) will be collected.

Intervention type: OTHER
Intervention: psychological and sociological interviews
Description: conducting semi-directive psychological interviews (40 interviews in M2, 40 interviews in M6).~sociological interviews: 40 (20 in M1-M2 then 20 in M6) in order to understand the consequences of the epidemic on daily life, both intra-family and micro-social.
Study: NCT00005604

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01241617

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duet TRS
Description: Endo GIA stapler with integrated Duet TRS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endo GIA
Description: Endo GIA stapler with Single Use Loading Units
Study: NCT02278367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: IV injection, 370 MBq (10 mCi), up to two doses

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET scan
Description: positron emission tomography (PET) scan of the brain
Study: NCT04808232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive muscle relaxation exercise
Description: We used the muscle relaxation audio CD produced by the Turkish Psychologists Association. The CD consists of three parts; the 10-min first part includes definition and purpose of relaxation, and points to take into consideration during relaxation, the 30-min second part includes instructions with river sounds, and the 30-min third part includes only relaxing music without instructions. We used the second part of the audio record in this study. Following the instructions on the CD, the students tensed each muscle group from hands to feet, and then, all muscles in their face and body for approximately 10 s. The women breathed in, tensed a specific muscle group, and then relaxed it while breathing out. The relaxation step took 10-20 s before tensing the next muscle group. Thus, the women relaxed by tensing and relaxing the muscle groups in hands, arms, neck, shoulder, chest, stomach, hips, foot and fingers, and all muscles in the face and body.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive muscle relaxation exercise
Description: We used the muscle relaxation audio CD produced by the Turkish Psychologists Association. The CD consists of three parts; the 10-min first part includes definition and purpose of relaxation, and points to take into consideration during relaxation, the 30-min second part includes instructions with river sounds, and the 30-min third part includes only relaxing music without instructions. We used the second part of the audio record in this study. Following the instructions on the CD, the students tensed each muscle group from hands to feet, and then, all muscles in their face and body for approximately 10 s. The women breathed in, tensed a specific muscle group, and then relaxed it while breathing out. The relaxation step took 10-20 s before tensing the next muscle group. Thus, the women relaxed by tensing and relaxing the muscle groups in hands, arms, neck, shoulder, chest, stomach, hips, foot and fingers, and all muscles in the face and body.
Study: NCT03968224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/Metformin
Description: Two tablets of Metformin 850 mg every 12 hours will be provided in combination with Dapagliflozin 10 mg per day. Each participant will receive diet and exercise intervention according to their BMI and current physical condition.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Two tablets of Metformin 850 mg every 12 hours will be provided. Each participant will receive diet and exercise intervention according to their BMI and current physical condition.
Study: NCT02314169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT03430661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching ACT-246475 placebo will consist of sterile 0.9% w/v sodium chloride solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching ACT-246475 placebo will consist of sterile 0.9% w/v sodium chloride solution
Study: NCT02314169

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT02212301

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: Each study contact lens will be worn as daily wear modality for a period of 2 weeks each.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: Each study contact lens will be worn as daily wear modality for a period of 2 weeks each.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: Each study contact lens will be worn as daily wear modality for a period of 2 weeks each.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: Each study contact lens will be worn as daily wear modality for a period of 2 weeks each.
Study: NCT01641627

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: proprioceptive stimulation
Description: tendon vibrations and plantar stimulation with a therapeuthic orthosis, 4x30 min/day during 14 days
Study: NCT03122405

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RAM sensors
Description: Noninvasive acoustic monitoring device
Study: NCT04937205

Intervention type: BEHAVIORAL
Intervention: MOVE
Description: The MOVE physical activity support program is based on the Self-Determination Theory and targets autonomous motivation for physical activity by encouraging 1) choice in physical activity type (e.g. walking, household chores, yoga), 2) a meaningful, value-based rationale for engaging in physical activity, and 3) physical activity that is intrinsically enjoyable. MOVE was delivered during two, 60-75 minute group-based classes and one, 45 minute individualized 1:1 support session to enhance adherence to physical activity recommendations within a lifestyle weight loss program. The group-based classes included a combination of PowerPoint slides, participant handouts, and group-based discussions. All MOVE content was delivered by trained study staff.

Intervention type: BEHAVIORAL
Intervention: MOVE
Description: The MOVE physical activity support program is based on the Self-Determination Theory and targets autonomous motivation for physical activity by encouraging 1) choice in physical activity type (e.g. walking, household chores, yoga), 2) a meaningful, value-based rationale for engaging in physical activity, and 3) physical activity that is intrinsically enjoyable. MOVE was delivered during two, 60-75 minute group-based classes and one, 45 minute individualized 1:1 support session to enhance adherence to physical activity recommendations within a lifestyle weight loss program. The group-based classes included a combination of PowerPoint slides, participant handouts, and group-based discussions. All MOVE content was delivered by trained study staff.

Intervention type: BEHAVIORAL
Intervention: MOVE
Description: The MOVE physical activity support program is based on the Self-Determination Theory and targets autonomous motivation for physical activity by encouraging 1) choice in physical activity type (e.g. walking, household chores, yoga), 2) a meaningful, value-based rationale for engaging in physical activity, and 3) physical activity that is intrinsically enjoyable. MOVE was delivered during two, 60-75 minute group-based classes and one, 45 minute individualized 1:1 support session to enhance adherence to physical activity recommendations within a lifestyle weight loss program. The group-based classes included a combination of PowerPoint slides, participant handouts, and group-based discussions. All MOVE content was delivered by trained study staff.
Study: NCT04730076

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Balloon Dilation
Description: The standard approach involves a gradual balloon dilation where the balloon is inflated then held at each balloon size for 30-60 seconds then inflated to the next largest balloon diameter size and repeated to the maximum diameter size of that catheter. The dilation session will be repeated as frequently and as many times as needed to achieve the balloon diameter size of 18mm at the discretion of the endoscopist.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Progressive Balloon Dilation
Description: In the progressive approach, the balloon is continuously inflated over the course of 3-5 minutes starting at the smallest to the largest balloon diameter depending of the balloon catheter used. The dilation will be repeated every 2-3 weeks (total of 2-3 sessions). At the next endoscopic procedure, the balloon diameter used will be the next size up based on previous session.
Study: NCT04101019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Intervention will include the SPGB block which will be performed by placing the patient supine with the neck extended and 1.5 ml of 5% lidocaine will be dripped into one or two nostrils.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Intervention will include the SPGB block which will be performed by placing the patient supine with the neck extended and 1.5 ml of saline will be dripped into one or two nostrils.
Study: NCT02806596

Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane
Description: After at least 4 minutes of stable inspired sevoflurane concentration, that concentration will be titrated to obtain a targeted bispectral index (BIS) level required for perform laryngoscopy. This level was initially set at 40, based on a preliminary study showing that such level of BIS was obtained at the laryngoscopy after common general anesthesia induction. For the next patients, BIS target was set according to a sequential allocation method (up and down).